The short-chain fatty acid propionate increases glucagon and FABP4 production, impairing insulin action in mice and humans.
Journal
Science translational medicine
ISSN: 1946-6242
Titre abrégé: Sci Transl Med
Pays: United States
ID NLM: 101505086
Informations de publication
Date de publication:
24 04 2019
24 04 2019
Historique:
received:
06
08
2018
accepted:
22
10
2018
entrez:
26
4
2019
pubmed:
26
4
2019
medline:
19
5
2020
Statut:
ppublish
Résumé
The short-chain fatty acid propionate is a potent inhibitor of molds that is widely used as a food preservative and endogenously produced by gut microbiota. Although generally recognized as safe by the U.S. Food and Drug Administration, the metabolic effects of propionate consumption in humans are unclear. Here, we report that propionate stimulates glycogenolysis and hyperglycemia in mice by increasing plasma concentrations of glucagon and fatty acid-binding protein 4 (FABP4).
Identifiants
pubmed: 31019023
pii: 11/489/eaav0120
doi: 10.1126/scitranslmed.aav0120
pii:
doi:
Substances chimiques
Fatty Acid-Binding Proteins
0
Propionates
0
Glycogen
9005-79-2
Glucagon
9007-92-5
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIDDK NIH HHS
ID : K08 DK097145
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK040561
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.